Resveratrol ameliorates cardiac hypertrophy by down-regulation of miR-155 through activation of breast cancer type 1 susceptibility protein

Journal of the American Heart Association

Volumn 5, Issue 4, 2016, Pages

  Fan, Yuhua ^a   Liu, Li ^a   Fang, Kun ^a   Huang, Tao ^a   Wan, Lin ^a   Liu, Youbin ^a   Zhang, Sen ^a   Yan, Dongxia ^a   Li, Guangnan ^a   Gao, Yanhui ^a   Lv, Yanjie ^a   Chen, Yanjun ^a   Tu, Yingfeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

BRCA1; FoxO3a; miR 155; Resveratrol

Indexed keywords

BRCA1 PROTEIN; ISOPRENALINE; MICRORNA 155; RESVERATROL; TRANSCRIPTION FACTOR FKHRL1; ENZYME INHIBITOR; MICRORNA; MIRN155 MICRORNA, MOUSE; RNA; STILBENE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; CELL CULTURE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRCA1 PROTEIN; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICRORNAS; MYOCYTES, CARDIAC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STILBENES;

EID: 84995691176     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002648     Document Type: Article

References (34)

1. Xu B, Zhu JX, Huo R, Yan ZY, He JL, Deng L, Wang JX, He J, Qiao GF, Chen H, Li BY. Alternations of cardiac IK1 and Ito from FKBP12.6 transgenic mouse heart and potential impact of cardiac hypertrophy. Int J Cardiol. 2014;176:1017-1020.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
3. van Zwieten PA. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovasc Res. 2000;45:82-91.
4. Bosutti A, Degens H. The impact of resveratrol and hydrogen peroxide on muscle cell plasticity shows a dose-dependent interaction. Sci Rep. 2015;5:8093.
5. Sung MM, Das SK, Levasseur J, Byrne NJ, Fung D, Kim TT, Masson G, Boisvenue J, Soltys CL, Oudit GY, Dyck JR. Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism. Circ Heart Fail. 2015;8:128-137.
6. Yang DL, Zhang HG, Xu YL, Gao YH, Yang XJ, Hao XQ, Li XH. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol. 2010;37:150-155.
7. Dolinsky VW, Soltys CL, Rogan KJ, Chan AY, Nagendran J, Wang S, Dyck JR. Resveratrol prevents pathological but not physiological cardiac hypertrophy. J Mol Med (Berl). 2015;93:413-425.
8. Jiang Q, Greenberg RA. Deciphering the BRCA1 tumor suppressor network. J Biol Chem. 2015;290:17724-17732.
9. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
10. Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basallike breast cancer cells. Mol Cell Biol. 2014;34:3828-3842.
11. Schott P, Singer SS, Kogler H, Neddermeier D, Leineweber K, Brodde OE, Regitz-Zagrosek V, Schmidt B, Dihazi H, Hasenfuss G. Pressure overload and neurohumoral activation differentially affect the myocardial proteome. Proteomics. 2005;5:1372-1381.
12. Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, Cao L, Rovira II, Pan Y, Brezden-Masley C, Yanagawa B, Gupta A, Deng CX, Coles JG, Leong-Poi H, Stanford WL, Parker TG, Schneider MD, Finkel T, Verma S. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun. 2011;2:593.
13. Musumeci M, Maccari S, Corritore E, Massimi A, Stati T, Marano G, Catalano L. Signaling pathway-focused gene expression profiling in pressure overloaded hearts. Ann Ist Super Sanita. 2011;47:290-295.
14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
15. Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, Stuhrmann M, Givens RC, Kennel PJ, Schulze PC, Widder JD, Bauersachs J, Thum T. Bloodbased microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 2015;196:115-122.
16. Li C, Li X, Gao X, Zhang R, Zhang Y, Liang H, Xu C, Du W, Liu X, Ma N, Xu Z, Wang L, Chen X, Lu Y, Ju J, Yang B, Shan H. MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol. 2014;173:268-276.
17. Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem. 2010;285:11903-11912.
18. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T, Shimatsu A, Hasegawa K. MicroRNA-1 and microRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. Circ J. 2009;73:1492-1497.
19. Tu Y, Wan L, Zhao D, Bu L, Dong D, Yin Z, Cheng Z, Shen B. In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. Eur J Nucl Med Mol Imaging. 2014;41:972-984.
20. Curtis AM, Fagundes CT, Yang G, Palsson-McDermott EM, Wochal P, McGettrick AF, Foley NH, Early JO, Chen L, Zhang H, Xue C, Geiger SS, Hokamp K, Reilly MP, Coogan AN, Vigorito E, FitzGerald GA, O'Neill LA. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. Proc Natl Acad Sci USA. 2015;112:7231-7236.
21. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stoger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schurmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128:1420-1432.
22. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, Hu X, Wang DZ. Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res. 2014;114:1585-1595.
23. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011;17:1275-1282.
24. Sun B, Huo R, Sheng Y, Li Y, Xie X, Chen C, Liu HB, Li N, Li CB, Guo WT, Zhu JX, Yang BF, Dong DL. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension. 2013;61:352-360.
25. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem. 2008;283:24194-24201.
26. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek M, van Leeuwen R, Gijbels MJ, Wijnands E, Biessen EA, De Winther MP, Stassen FR, Carmeliet P, Kauppinen S, Schroen B, Heymans S. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res. 2012;111:415-425.
27. Tan WQ, Wang K, Lv DY, Li PF. Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J Biol Chem. 2008;283:29730-29739.
28. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FoxO3a in breast cancer. J Biol Chem. 2010;285:17869-17879.
29. Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT, Li X. MicroRNA-155 regulates cell proliferation and invasion by targeting FoxO3a in glioma. Oncol Rep. 2013;30:2111-2118.
30. Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, Hohlfeld R, Meinl E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009;132:3342-3352.
31. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D. Altered expression of microrna in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58:1001-1009.
32. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276-2288.
33. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K. The FoxO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem. 2005;280:20814-20823.
34. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics. 1998;47:187-199.